Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | FFAR2 | O15552 | 9/20 | 0.63 |
| ▸ | MEN1 | O00255 | 4/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.49 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.49 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.49 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1565491 | 0.89 | NPC1 (0.54) | LMNAFFAR2MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1565145 | 0.89 | LMNA (0.66) | LMNAFFAR2MEN1KMT2ASCN3A | |
| SCHEMBL1565596 | 0.89 | LMNA (0.66) | LMNAFFAR2MEN1KMT2ASCN3A | |
| SCHEMBL1565489 | 0.82 | LMNA (0.56) | LMNAFFAR2MEN1KMT2ANPC1 | |
| SCHEMBL1565420 | 0.82 | NPC1 (0.60) | LMNAFFAR2MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2655931 | 0.81 | GCK (0.66) | LMNAFFAR2MEN1KMT2ASCN3A | |
| SCHEMBL2656245 | 0.80 | GCK (0.61) | LMNAFFAR2MEN1KMT2ASCN3A | |
| SCHEMBL1565536 | 0.79 | LMNA (0.56) | LMNAFFAR2MEN1KMT2ANPC1 | |
| SCHEMBL1565031 | 0.78 | S1PR1 (0.62) | FFAR2MEN1KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL1565319 | 0.77 | NPC1 (0.54) | LMNAFFAR2MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100506807-C | Amide derivatives as GK activators | NOVO NORDISK AS (DK) | 2009-07-01 | — | — | CN | claimed |
| CN-101434585-A | Amide derivatives as GK activators | NOVO NORDISK AS (DK) | 2009-05-20 | — | — | CN | claimed |
| US-20030171411-A1 | Amide derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2003-09-11 | — | — | US | claimed |
| EP-1336607-A1 | Amide derivatives as glucokinase activators | NOVO NORDISK A/S (DK) | 2003-08-20 | — | — | EP | claimed |
| EP-2305648-A1 | Amide derivatives useful as glucokinase activators | Novo Nordisk A/S (DK) | 2011-04-06 | — | — | EP | disclosed |
| EP-2305648-A1 | Amide derivatives useful as glucokinase activators | Novo Nordisk A/S (DK) | 2011-04-06 | — | — | EP | disclosed |
| CN-100506807-C | Amide derivatives as GK activators | NOVO NORDISK AS (DK) | 2009-07-01 | — | — | CN | disclosed |
| CN-101434585-A | Amide derivatives as GK activators | NOVO NORDISK AS (DK) | 2009-05-20 | — | — | CN | disclosed |
| EP-1458382-A1 | AMIDE DERIVATIVES AS GK ACTIVATORS | NOVO NORDISK A/S (DK) | 2004-09-22 | — | — | EP | disclosed |
| US-20030171411-A1 | Amide derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2003-09-11 | — | — | US | disclosed |
| EP-1336607-A1 | Amide derivatives as glucokinase activators | NOVO NORDISK A/S (DK) | 2003-08-20 | — | — | EP | disclosed |
| WO-2003055482-A1 | AMIDE DERIVATIVES AS GK ACTIVATORS | NOVO NORDISK A/S (DK) | 2003-07-10 | — | — | WO | disclosed |
| WO-2003055482-A1 | AMIDE DERIVATIVES AS GK ACTIVATORS | NOVO NORDISK A/S (DK) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171411-A1 | Amide derivatives as therapeutic agents | GK, GCKR, GCK | LMNA 3743/4885FFAR2 286/4885MEN1 3187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.